Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARMOUR Residential REIT, Inc. (ARR) vs Boston Scientific Corporation (BSX) Price & Performance

ARMOUR Residential REIT, Inc.Trade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

ARMOUR Residential REIT, Inc. vs Boston Scientific Corporation — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.72 (market cap $2.07B), while Boston Scientific Corporation trades at $51.07 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 35.8× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

ARRBSX
Market Cap
$2.07B$74.19B
Sector
FinancialsHealth
52-Week High
$19.12$108.14
52-Week Low
$14.05$42.63
Dividend Yield
17.28%
Enterprise Value
$86.27B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.

Read more on ARR

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX